

**5th DIA Cell and Gene Therapy Products Symposium in Japan** 

- Regenerative Medicine from Innovation to Industrialization -

December 10-11, 2020

# Challenge to comparability evaluation and change control of Cell Therapy Product

## Kazumi SAWAGUCHI, Ph.D SanBio Company Limited Regulatory Affairs

Notice: Some of the materials have been modified from the original version for publication on our website.



The Company's plans, strategies, and judgements included in this material—except for those relating to actual, historical data from the past—are based on our view of the future business outlook at the time this material was prepared, formulated with information available to us at that time and assumptions and judgements based on it. Therefore, actual outcomes, achievements, and financial results to be announced in the future may differ from information provided in this material due to various factors including changes in the future business environment.

This material also contains information pertaining to the Company's development programs and other businesses, but it is not intended for the purposes of promotion or advertising, or providing medical advice.

Information provided in this material may be revised without prior notice. The Company or the persons providing this information do not assume any responsibility for damages that may arise because of matters relating to this material.

SanBio Co., Ltd.



- SB623 are modified allogeneic mesenchymal stromal cells(MSC) transiently transfected with human Notch-1 intracellular domain
- Implantation of SB623 cells in the peri-infarct region



# SanBio: History




	Corporate	Development           Non-clin.         Clinical         CMO         Lab				
2001 2002	<ul> <li>Feb Established Sanbio, Inc. in the US (California)</li> <li>Nov Technical transfer from YOKOHAMA TLO KK (SB623)</li> </ul>	Non-clin.	Clinical Basic Research Process Developr		Luo	
2010	May SB623 Phase I/IIa IND (US)			Plant A		
2013	Feb Established SanBio KK in Japan	Non-GLP	[US] Phase I/IIa			
2014	May SB623 Phase IIb (Indication A) IND (US) Jan Reversal JP-US parent-Child (JP subsidiary as Parents Comp.)	GLP		Plant B	Process Development	
2015	Apr Listed on Mothers					
2016	Mar IND (JP)		[US] Phase IIa (Ind.A) [JP/US/EU] PhaseII (Ind.B)			
2020	Nov Present			Plant C		

\*POC: Proof of Concept

## **Allogeneic Approach**




#### Select Allogeneic Model in Order to Make RM Available to All Patients






### Large Scale Production of Cells Derived From Bone Marrow





- It is difficult to grasp all the quality of cell therapy product by the Spec., as the information is limited.
- The idea of quality control by controlling raw materials and manufacturing processes is important.




Ref. R.Maruyama et.al Perspectives and practical strategies for obtaining approval / reviewing products for regenerative medicine / gene therapy products, Science & Technology, 2020.9 P 186

# **Strategy of Scale-up Manufacturing from Lab to CPC**



## It Takes Time to Develop Large Scale Production Technology




©2020 SanBio Company Limited



- Raw Materials (Human-derived materials)
  - Risk of infection/Viral contamination
  - Material variability/Donor-to-donor variability
- Process Development
  - Knowledge management from academic field
  - Comparability for process changes (e.g. scale up)
  - Limited materials for process evaluation
  - Identification of CPP (Critical Process Parameter) and CQA (Critical Quality Attribute)
- Manufacturing control
  - GCTP
  - Aseptic process considerations
  - Viral safety considerations
  - Process performance consistency
- Analysis
  - Complex characteristics
  - Specification (potency assay etc.)





\* CMC: Chemistry, Manufacturing and Control

## **Quality characteristics of cell therapy products**




Ref. The 16<sup>th</sup> Congress of the Japanese Society for Regenerative Medicine PMDA Dr. Oyama 2017

Evaluation item	Example of test method (Case by Case depending on the position of the test)		
Identity test	Description, Cell phenotype, Differentiation ability, Tumorigenesis etc.		
Cell purity test	Cell phenotype, Proliferation abnormality etc.		
Process-related Impurities	Manufacturing process-related substances (Serum-related Albumin, Antibiotics, etc.)		
Unintended Product-related physiologically active impurities	Physiologically active substances, etc.		
Safety	Chromosome abnormality, Soft agar colony forming ability, Virus, Mycoplasma, Endotoxin, Sterility, etc. (secured as in-process control)		
Potency assay, efficacy test, Mechanical compatibility	Protein expression, Secretion ability, Differentiation ability, Cell phenotype, Cell proliferation ability, Cell survival, Cell/cell interaction etc.		
Content	No of cell, Cell viability, etc.		

\*Quality characteristics related to efficacy and safety can be important quality characteristics, but it is still necessary to organize and discuss what kind of quality characteristics correspond to each product containing cells.

\* We can debate about what quality characteristic items and standard values should be set in the titer test.






Quantify various biologically active substance in culture supernatant using antibody array kit.

#### Can these active substance be subject to "Potency assay"?


Ref: Tate et al, : Cell Transplant 2010; 19(8): 973–984 revised






Consider to set the specification for Cell therapy product SanBi

Ref. The 16th Congress of the Japanese Society for Regenerative Medicine PMDA Dr. Oyama 2017




- For Cell therapy product
- 1. Cells are alive
- 2. Quality characteristics are complex, diverse and heterogeneous
- 3. There are technical restrictions on the implementation of specification tests and manufacturing control
- 4. The specification only confirms an important part of quality and can only be established on various assumptions.
- Points to consider
- 1. Full understanding of quality characteristics (characteristic analysis)
- 2. Understanding process variations that lead to quality fluctuations (quality risk management)
- 3. Invisible quality parts should be managed as quality fluctuations from the upstream of the process (quality control strategy)












Ref. IABS, JST(NIBIO), PMDA and WHO joint Workshop Dr.Sato Feb 2015





Ref. IABS, JST(NIBIO), PMDA and WHO joint Workshop Dr.Sato Feb 2015

